Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy.
Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy.
复制标题
DOI：
10.1155/2015/857416
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Sakai H
中科院分区：
文献类型：
--
作者：
Miyata Y;Sakai H
高复发率是膀胱癌的代表性特征之一。非肌层浸润性膀胱癌（NMIBC）患者经尿道切除术后常进行膀胱内治疗以防止复发。卡介苗（BCG）和几种抗癌/抗生素药物，如丝裂霉素C和表阿霉素，通常用于这种治疗。BCG治疗显示出强大的抗癌作用。然而，它也具有不良事件发生频率高的特点。另一方面，虽然使用其他抗癌剂和抗生素的膀胱内治疗相对安全，但其抗癌效果低于使用BCG获得的效果。因此，选择合适的药物进行膀胱内治疗对于改善NMIBC患者的治疗结果和维持其生活质量非常重要。在这篇综述中，我们讨论了各种组织学和分子标志物对NMIBC患者膀胱内治疗后复发的预测价值。
High recurrence rate is one representative characteristic of bladder cancer. Intravesical therapy after transurethral resection is often performed in patients with nonmuscle invasive bladder cancer (NMIBC) to prevent recurrence. Bacillus Calmette-Guérin (BCG) and several anticancer/antibiotic agents, such as mitomycin C and epirubicin, are commonly used for this therapy. BCG treatment demonstrates strong anticancer effects. However, it is also characterized by a high frequency of adverse events. On the other hand, although intravesical therapies using other anticancer and antibiotic agents are relatively safe, their anticancer effects are lower than those obtained using BCG. Thus, the appropriate selection of agents for intravesical therapy is important to improve treatment outcomes and maintain the quality of life of patients with NMIBC. In this review, we discuss the predictive value of various histological and molecular markers for recurrence after intravesical therapy in patients with NMIBC.
影响因子：
2.6
作者：
Okamura, Takehiko;Ando, Ryosuke;Akita, Hidetoshi;Kawai, Noriyasu;Tozawa, Keiichi;Kohri, Kenjiro;Arano, Hideo
通讯作者：
Arano, Hideo